153 related articles for article (PubMed ID: 26433443)
21. Relationship among initial serum prostate specific antigen, prostate specific antigen progression and prostate cancer detection at repeat screening visits.
Candas B; Labrie F; Gomez JL; Cusan L; Chevrette E; Lévesque J; Brousseau G
J Urol; 2006 Feb; 175(2):510-6; discussion 516-7. PubMed ID: 16406983
[TBL] [Abstract][Full Text] [Related]
22. Selecting men diagnosed with prostate cancer for active surveillance using a risk calculator: a prospective impact study.
van Vugt HA; Roobol MJ; van der Poel HG; van Muilekom EH; Busstra M; Kil P; Oomens EH; Leliveld A; Bangma CH; Korfage I; Steyerberg EW
BJU Int; 2012 Jul; 110(2):180-7. PubMed ID: 22112199
[TBL] [Abstract][Full Text] [Related]
23. Unravelling the prostate-specific antigen controversy: a West of Scotland perspective.
Zafar N; Miller S; Leburn V; Qureshi KN; Rajan P
Scott Med J; 2014 May; 59(2):126-9. PubMed ID: 24682103
[TBL] [Abstract][Full Text] [Related]
24. The effect of obesity and lower serum prostate-specific antigen levels on prostate-cancer screening results in American men.
Culp S; Porter M
BJU Int; 2009 Nov; 104(10):1457-61. PubMed ID: 19522868
[TBL] [Abstract][Full Text] [Related]
25. Educating men about prostate cancer screening. A randomized trial of a mailed pamphlet.
Wilt TJ; Paul J; Murdoch M; Nelson D; Nugent S; Rubins HB
Eff Clin Pract; 2001; 4(3):112-20. PubMed ID: 11434074
[TBL] [Abstract][Full Text] [Related]
26. Survey of urologists on clients' demand for screening for prostate cancer in Nigeria.
Ajape AA; Mustapha K; Lawal IO; Mbibu HN
Niger J Clin Pract; 2011; 14(2):151-3. PubMed ID: 21860129
[TBL] [Abstract][Full Text] [Related]
27. Prostate cancer screening practices and beliefs.
Voss JD; Schectman JM
J Gen Intern Med; 2001 Dec; 16(12):831-7. PubMed ID: 11903762
[TBL] [Abstract][Full Text] [Related]
28. Total and percent free prostate-specific antigen levels among U.S. men, 2001-2002.
Saraiya M; Kottiri BJ; Leadbetter S; Blackman D; Thompson T; McKenna MT; Stallings FL
Cancer Epidemiol Biomarkers Prev; 2005 Sep; 14(9):2178-82. PubMed ID: 16172229
[TBL] [Abstract][Full Text] [Related]
29. What influences family physicians' cancer screening decisions when practice guidelines are unclear or conflicting?
Tudiver F; Guibert R; Haggerty J; Ciampi A; Medved W; Brown JB; Herbert C; Katz A; Ritvo P; Grant B; Goel V; Smith P; O'Beirne M; Williams JI; Moliner P
J Fam Pract; 2002 Sep; 51(9):760. PubMed ID: 12366894
[TBL] [Abstract][Full Text] [Related]
30. Measuring the psychosocial impact of population-based prostate-specific antigen testing for prostate cancer in the UK.
Brindle LA; Oliver SE; Dedman D; Donovan JL; Neal DE; Hamdy FC; Lane JA; Peters TJ
BJU Int; 2006 Oct; 98(4):777-82. PubMed ID: 16978272
[TBL] [Abstract][Full Text] [Related]
31. Attitudes and practices of primary care physicians for prostate cancer screening.
Hoffman RM; Papenfuss MR; Buller DB; Moon TE
Am J Prev Med; 1996; 12(4):277-81. PubMed ID: 8874692
[TBL] [Abstract][Full Text] [Related]
32. Prostate cancer screening trends of New York State men at least 50 years of age, 1994 to 1997.
McDavid K; Melnik TA; Derderian H
Prev Med; 2000 Sep; 31(3):195-202. PubMed ID: 10964632
[TBL] [Abstract][Full Text] [Related]
33. Prostate-specific antigen screening: friend or foe?
Linn MM; Ball RA; Maradiegue A
Urol Nurs; 2007 Dec; 27(6):481-9; quiz 490. PubMed ID: 18217530
[TBL] [Abstract][Full Text] [Related]
34. A test of knowledge about prostate cancer screening. Online pilot evaluation among Southern California Physicians.
Bell DS; Hays RD; Hoffman JR; Day FC; Higa JK; Wilkes MS
J Gen Intern Med; 2006 Apr; 21(4):310-4. PubMed ID: 16499545
[TBL] [Abstract][Full Text] [Related]
35. Prostate cancer screening in men 75 years old or older: an assessment of self-reported health status and life expectancy.
Hoffman KE; Nguyen PL; Ng AK; D'Amico AV
J Urol; 2010 May; 183(5):1798-802. PubMed ID: 20299039
[TBL] [Abstract][Full Text] [Related]
36. PSA screening: a public health dilemma.
Mandelson MT; Wagner EH; Thompson RS
Annu Rev Public Health; 1995; 16():283-306. PubMed ID: 7543756
[TBL] [Abstract][Full Text] [Related]
37. Prostate cancer screening at an equal access tertiary care center: its impact 10 years after the introduction of PSA.
Soderdahl DW; Hernandez J
Prostate Cancer Prostatic Dis; 2002; 5(1):32-5. PubMed ID: 15195128
[TBL] [Abstract][Full Text] [Related]
38. The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer.
Wilt TJ; Brawer MK; Barry MJ; Jones KM; Kwon Y; Gingrich JR; Aronson WJ; Nsouli I; Iyer P; Cartagena R; Snider G; Roehrborn C; Fox S
Contemp Clin Trials; 2009 Jan; 30(1):81-7. PubMed ID: 18783735
[TBL] [Abstract][Full Text] [Related]
39. Practice patterns regarding prostate cancer and benign prostatic hyperplasia in Japanese primary care practitioners.
Fukagai T; Maruyama K; Nagata M; Morita M; Naoe M; Yoshida H
Int J Urol; 2007 May; 14(5):412-5. PubMed ID: 17511723
[TBL] [Abstract][Full Text] [Related]
40. Screening for prostate cancer in New Zealand general practice.
Zuzana O; Ross L; Fraser H; Charis B; Alistair S; Leanne T; Michael H; Peter G
J Med Screen; 2013 Mar; 20(1):49-51. PubMed ID: 23612467
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
